These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15947553)

  • 41. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Hsu CA; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Feb; 57(2):441-50. PubMed ID: 22941922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers.
    Ijaz B; Ahmad W; Javed FT; Gull S; Hassan S
    Virol J; 2011 Feb; 8():86. PubMed ID: 21352567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
    Brunetto MR; Giarin MM; Oliveri F; Chiaberge E; Baldi M; Alfarano A; Serra A; Saracco G; Verme G; Will H
    Proc Natl Acad Sci U S A; 1991 May; 88(10):4186-90. PubMed ID: 2034663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers.
    Fujiwara K; Yokosuka O; Ehata T; Chuang WL; Imazeki F; Saisho H; Omata M
    Dig Dis Sci; 1998 Feb; 43(2):368-76. PubMed ID: 9512133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels.
    Lin CL; Liao LY; Liu CJ; Yu MW; Chen PJ; Lai MY; Chen DS; Kao JH
    Hepatology; 2007 May; 45(5):1193-8. PubMed ID: 17464993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection and characterization of hepatitis B virus DNA in serum of HBe antigen-negative HBsAg carriers.
    Tur-Kaspa R; Keshet E; Eliakim M; Shouval D
    J Med Virol; 1984; 14(1):17-26. PubMed ID: 6747609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Natural history of hepatitis B virus infection in dialysis patients: prospective study by quantitative analysis of HBV viremia].
    Fabrizi F; Lunghi G; Finazzi S; Colucci P; Pagliari B; Bisegna S; Tettamanzi F; Ponticelli C
    G Ital Nefrol; 2002; 19(3):294-300. PubMed ID: 12195397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Study on the correlation among quantification of HBV-DNA and HBeAg, anti-HBe in hepatitis B carriers].
    Dou YL; Cheng XQ; Li YZ; Han JH; Ni AP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Aug; 27(8):709-11. PubMed ID: 17172114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis B virus-DNA in the serum of patients followed-up longitudinally with acute and chronic hepatitis B.
    Moestrup T; Hansson BG; Widell A; Blomberg J; Nordenfelt E
    J Med Virol; 1985 Dec; 17(4):337-44. PubMed ID: 4078560
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa.
    Boyd A; Kouamé MG; Houghtaling L; Moh R; Gabillard D; Maylin S; Abdou Chekaraou M; Delaugerre C; Anglaret X; Eholié SP; Danel C; Zoulim F; Lacombe K;
    Trans R Soc Trop Med Hyg; 2019 Aug; 113(8):437-445. PubMed ID: 31574151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low HBV-DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B.
    Moutinho RS; Perez RM; Medina-Pestana JO; Figueiredo MS; Koide S; Alberto FL; Silva AE; Ferraz ML
    J Med Virol; 2006 Oct; 78(10):1284-8. PubMed ID: 16927290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of hepatitis B virus DNA directly in human serum by a simplified molecular hybridization test: comparison to HBeAg/anti-HBe status in HBsAg carriers.
    Lieberman HM; LaBrecque DR; Kew MC; Hadziyannis SJ; Shafritz DA
    Hepatology; 1983; 3(3):285-91. PubMed ID: 6301965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microwave treatment of serum facilitates detection of hepatitis B virus DNA by the polymerase chain reaction. Results of a study in anti-HBe positive chronic hepatitis B.
    Costa J; López-Labrador FX; Sánchez-Tapias JM; Mas A; Vilella A; Olmedo E; Vidal J; Jimenez de Anta MT; Rodés J
    J Hepatol; 1995 Jan; 22(1):35-42. PubMed ID: 7751585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum ALT levels as a surrogate marker for serum HBV DNA levels in HBeAg-negative pregnant women.
    Sangfelt P; Von Sydow M; Uhnoo I; Weiland O; Lindh G; Fischler B; Lindgren S; Reichard O
    Scand J Infect Dis; 2004; 36(3):182-5. PubMed ID: 15119362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals.
    Huang H; Wang J; Li W; Chen R; Chen X; Zhang F; Xu D; Lu F
    J Clin Virol; 2018; 99-100():71-78. PubMed ID: 29353073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.